Clinical Trials

Head & NeckOther solid neoplasm

340 enrolled 53 charts

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2/3 Completed

196 enrolled 31 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

19 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

13 enrolled 12 charts

Head and Neck Neoplasms

NCT03739931 2025-08-15

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

134 enrolled

Head & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Lymphoma

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

18 enrolled 10 charts

Phase EARLY_PHASE1 Active not recruiting

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

11 enrolled 6 charts

Thyroid Neoplasms

NCT03635164 2025-06-27

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

21 enrolled

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Completed

38 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

GastrointestinalHead & NeckThoracic

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03726775 2025-05-07

REWRITe

61 enrolled

Phase EARLY_PHASE1 Terminated

Squamous Cell Carcinoma of Head and Neck

NCT02827838 2025-03-17

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

17 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Papillomavirus Infections

NCT03518606 2025-01-15

MOVIE

BreastGenitourinaryGynecologicHead & Neck

126 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03509012 2025-01-14

CLOVER

Phase 3 Active not recruiting

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04116047 2024-07-29

CompARE

785 enrolled

Phase 1/2 Active not recruiting

Oropharyngeal Neoplasms

NCT03784066 2024-07-03

DUTRELASCO

21 enrolled

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03283605 2024-06-28

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Phase 2 Completed

18 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03723967 2024-04-22

FRAIL-IMMUNE

Phase 2 Completed

104 enrolled

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT03691714 2023-12-08

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

36 enrolled

Head and Neck Neoplasms, Neoplasm Metastasis

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1/2 Terminated

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT03088059 2023-11-03

UPSTREAM

Phase 2 Unknown

340 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03624231 2023-08-31

DURTRE-RAD

Phase 2 Completed

18 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck

NCT03737968 2023-03-21

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Phase 2 Unknown

48 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Laryngeal Diseases

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04359199 2023-02-10

QUASAR

Unknown

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers